Oncotelic Therapeutics Chairman and CEO Vuong Trieu reports acquisition of $23,536.83 in common shares
OTLC•Chairman and CEO Vuong Trieu purchased 1,044,990 Oncotelic Therapeutics common shares at $0.017 each and another 312,000 at $0.0185 each. His direct beneficial ownership rose to 95,481,309 shares.
1. Share purchases
Vuong Trieu purchased 1,044,990 common shares at $0.017 each and a separate 312,000 shares at $0.0185 each. His direct beneficial ownership rose to 95,481,309 common shares following the purchases.
